-
公开(公告)号：US08999350B2
公开(公告)日：2015-04-07
申请号：US12989165
申请日：2009-04-22
Applicant: Erwann Loret
Inventor： Erwann Loret
IPC: A61K39/21 , A61K38/16 , C07K14/005 , A61K39/00
CPC classification number: A61K38/162 , A61K39/00 , A61K39/12 , A61K39/21 , A61K2039/53 , C07K14/005 , C12N2740/16322 , C12N2740/16334
Abstract: The invention relates to a method of preventing or treating acquired immunodeficiency syndrome (AIDS) in a patient, wherein the patient is administered with a Tat protein comprising amino acid sequence SEQ ID NO: 1 or 2, or a variant thereof capable of stimulating an immune response against Tat proteins.
Abstract translation: 本发明涉及一种预防或治疗患者中获得性免疫缺陷综合征（AIDS）的方法，其中向患者施用包含氨基酸序列SEQ ID NO：1或2的Tat蛋白或其能够刺激免疫的变体 对Tat蛋白的反应。
-
公开(公告)号：US20120121632A9
公开(公告)日：2012-05-17
申请号：US12989165
申请日：2009-04-22
Applicant: Erwann Loret
Inventor： Erwann Loret
CPC classification number: A61K38/162 , A61K39/00 , A61K39/12 , A61K39/21 , A61K2039/53 , C07K14/005 , C12N2740/16322 , C12N2740/16334
Abstract: The invention relates to a method of preventing or treating acquired immunodeficiency syndrome (AIDS) in a patient, wherein the patient is administered with a Tat protein comprising amino acid sequence SEQ ID NO: 1 or 2, or a variant thereof capable of stimulating an immune response against Tat proteins.
Abstract translation: 本发明涉及一种预防或治疗患者中获得性免疫缺陷综合征（AIDS）的方法，其中向患者施用包含氨基酸序列SEQ ID NO：1或2的Tat蛋白或其能够刺激免疫的变体 对Tat蛋白的反应。
-
公开(公告)号：US20110212118A1
公开(公告)日：2011-09-01
申请号：US12989165
申请日：2009-04-22
Applicant: Erwann Loret
Inventor： Erwann Loret
CPC classification number: A61K38/162 , A61K39/00 , A61K39/12 , A61K39/21 , A61K2039/53 , C07K14/005 , C12N2740/16322 , C12N2740/16334
Abstract: The invention relates to a method of preventing or treating acquired immunodeficiency syndrome (AIDS) in a patient, wherein the patient is administered with a Tat protein comprising amino acid sequence SEQ ID NO: 1 or 2, or a variant thereof capable of stimulating an immune response against Tat proteins.
Abstract translation: 本发明涉及一种预防或治疗患者中获得性免疫缺陷综合征（AIDS）的方法，其中向患者施用包含氨基酸序列SEQ ID NO：1或2的Tat蛋白或其能够刺激免疫的变体 对Tat蛋白的反应。
-
4.发明申请
公开(公告)号：US20050106161A1
公开(公告)日：2005-05-19
申请号：US10969191
申请日：2004-10-21
Applicant: Erwann Loret
Inventor： Erwann Loret
IPC: G01N33/53 , A61K6/00 , A61K38/00 , A61K39/00 , A61K39/21 , A61K39/39 , A61P31/18 , C07K14/16 , C07K16/10 , G01N33/569
CPC classification number: C07K14/005 , A61K39/00 , A61K39/12 , A61K39/21 , A61K2039/54 , A61K2039/545 , A61K2039/55566 , C12N2740/16322 , C12N2740/16334 , Y10S435/962 , Y10S435/974 , Y10S435/975
Abstract: The invention relates to an anti HIV 1 vaccine comprising the entire or part of the Tat HIV 1 protein, in addition to the identification of said protein in individuals affected by HIV. The Tat protein is a protein of the HIV1 Oyi variant.
Abstract translation: 本发明涉及包含Tat HIV 1蛋白的全部或部分的抗HIV 1疫苗，以及在受HIV感染的个体中鉴定所述蛋白质。 Tat蛋白是HIV1 Oyi变体的蛋白质。
-
5.发明授权
公开(公告)号：US07087377B2
公开(公告)日：2006-08-08
申请号：US10969191
申请日：2004-10-21
Applicant: Erwann Loret
Inventor： Erwann Loret
IPC: C12Q1/70
CPC classification number: C07K14/005 , A61K39/00 , A61K39/12 , A61K39/21 , A61K2039/54 , A61K2039/545 , A61K2039/55566 , C12N2740/16322 , C12N2740/16334 , Y10S435/962 , Y10S435/974 , Y10S435/975
Abstract: The invention relates to an anti HIV 1 vaccine comprising the entire or part of the Tat HIV 1 protein, in addition to the identification of said protein in individuals affected by HIV. The Tat protein is a protein of the HIV 1 Oyi variant.
Abstract translation: 本发明涉及包含Tat HIV 1蛋白的全部或部分的抗HIV 1疫苗，以及在受HIV感染的个体中鉴定所述蛋白质。 Tat蛋白是HIV 1 Oyi变体的蛋白质。
